Study of Pembrolizumab With or Without Platinumb-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (KEYNOTE-361)
The purpose of this study is to determine the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy versus chemotherapy alone in participants with advanced or metastatic urothelial carcinoma (bladder cancer).
Primary Sponsor: Merck
Prinicipal Investigator: Jianqing Lin, M.D./Medicine; Division of Hematology/Oncology
Contact Phone: 202-741-3379
Are you interested in more information on this clinical trial?